Navigation Links
InterMune to Present at J. P. Morgan Healthcare Conference
Date:1/5/2012

BRISBANE, Calif., Jan. 5, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that Dan Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco on January 11, 2012, at 12:30 p.m. EST / 9:30 a.m. PST.  

To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases. In pulmonology, InterMune is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. Pirfenidone, the only medicine approved worldwide for IPF, is approved for marketing by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial in the United States.  Pirfenidone is also approved for the treatment of IPF in Japan, where it is marketed by Shionogi & Co. Ltd. under the trade name Pirespa®. InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. InterMune to Present at Canaccord Adams Conference
2. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
3. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
4. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
5. InterMune to Release Third Quarter 2008 Financial Results on November 6
6. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
7. InterMune to Present at Deutsche Bank Biotech Boston Confab
8. InterMune to Present at J.P. Morgan Healthcare Conference
9. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
10. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
11. InterMune Announces Issuance of U.S. Patent for ITMN-191
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... -- Kineta, Inc., a biotechnology company focused on ... today announced the discovery and characterization of several ... interferon response factor 3 (IRF3) via RIG-I like ... in a murine colon carcinoma mouse model.  Furthermore, ... regression to initial drug treatment were resistant to ...
(Date:3/23/2017)... 23, 2017  Agriculture technology company Cool Planet has ... note conversion to commercialize its Cool Terra and Cool ... developing products that are simultaneously profitable as well as ... last 18 months. This latest round of funding was ... The company,s primary product, Cool Terra, ...
(Date:3/22/2017)... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced a ... Biobank and GSK to generate genetic sequence data from the ... will enable researchers to gain valuable insights to support advances ... of serious and life threatening diseases. ... Genetic evidence has revolutionized ...
(Date:3/22/2017)... March 22, 2017  UBM and the Massachusetts ... their extended partnership and the third annual Massachusetts Medtech ... the 21 st Annual MassMEDIC Conference held ... May 3-4, 2017. MassMEDIC will ... (ADVAMED) President and CEO, Scott Whitaker , ...
Breaking Biology Technology:
(Date:3/23/2017)... -- Research and Markets has announced the addition of ... Industry Forecast to 2025" report to their offering. ... The Global Vehicle Anti-Theft ... 8.8% over the next decade to reach approximately $14.21 billion by ... and forecasts for all the given segments on global as well ...
(Date:3/20/2017)... , March 20, 2017 At this year,s CeBIT ... -based biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand together ... is this year,s CeBIT partner country. At the largest German biometrics company ... use: fingerprint, face and iris recognition as well as DERMALOGĀ“s multi-biometrics system.   ... ...
(Date:3/9/2017)... Australia , March 9, 2017 ... the prestigious World Lung Imaging Workshop at the University ... , was invited to deliver the latest data to ... globally recognised event brings together leaders at the forefront ... developments in lung imaging. "The quality ...
Breaking Biology News(10 mins):